Suppr超能文献

市售桦树花粉变应原提取物的分子组成和生物活性。

Molecular composition and biological activity of commercial birch pollen allergen extracts.

作者信息

Focke M, Marth K, Valenta R

机构信息

Medical University of Vienna, Vienna, Austria.

出版信息

Eur J Clin Invest. 2009 May;39(5):429-36. doi: 10.1111/j.1365-2362.2009.02109.x.

Abstract

BACKGROUND

Commercial extracts used for diagnosis and treatment of allergy are currently prepared from natural allergen sources. The aim of this study was to analyse birch pollen allergen extracts produced for in vivo diagnosis of birch pollen allergy regarding their contents of individual birch pollen allergens (Bet v 1, Bet v 2 and Bet v 4).

METHODS

Protein contents were measured and the allergen composition was analysed by immunoblotting using antibody probes specific for Bet v 1, Bet v 2 and Bet v 4 in birch pollen extracts from five manufacturers of allergen extracts. The contents of the major birch pollen allergen, Bet v 1, were quantified with a specific two-site binding enzyme-linked immunosorbent assay with nanogram sensitivity for Bet v 1. The biological activities of the allergen extracts were evaluated by skin prick testing in birch pollen allergic patients and compared with their sensitization profiles.

RESULTS

A more than 10-fold variation regarding total protein contents (23.1-314 microg mL(-1)) and also regarding the amounts of the major birch pollen allergen, Bet v 1 (1.62-19.6 microg mL(-1)) was found. The highly cross-reactive Bet v 4 allergen was absent in three of the five tested extracts. Furthermore, varying skin test results were obtained in birch pollen allergic patients with the allergen extracts.

CONCLUSIONS

Commercial birch pollen extracts exhibit a considerable variability regarding allergen contents and hence deliver varying in vivo test results. These problems might be overcome with recombinant allergen-based preparations.

摘要

背景

目前用于过敏诊断和治疗的商业提取物是从天然过敏原来源制备的。本研究的目的是分析用于桦树花粉过敏体内诊断的桦树花粉过敏原提取物中各桦树花粉过敏原(Bet v 1、Bet v 2和Bet v 4)的含量。

方法

测量了来自五家过敏原提取物制造商的桦树花粉提取物中的蛋白质含量,并使用针对Bet v 1、Bet v 2和Bet v 4的特异性抗体探针通过免疫印迹分析过敏原组成。使用对Bet v 1具有纳克灵敏度的特异性双位点结合酶联免疫吸附测定法定量主要桦树花粉过敏原Bet v 1的含量。通过对桦树花粉过敏患者进行皮肤点刺试验评估过敏原提取物的生物活性,并将其与他们的致敏谱进行比较。

结果

发现总蛋白质含量(23.1 - 314微克/毫升)以及主要桦树花粉过敏原Bet v 1的含量(1.62 - 19.6微克/毫升)有超过10倍的差异。在五种测试提取物中的三种中未检测到高度交叉反应性的Bet v 4过敏原。此外,桦树花粉过敏患者使用过敏原提取物获得了不同的皮肤试验结果。

结论

商业桦树花粉提取物在过敏原含量方面表现出相当大的变异性,因此体内试验结果也各不相同。基于重组过敏原的制剂可能会克服这些问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验